Evidence map›Paper›PMID 40742314›Full record

ArticleFuture oncology (London, England)2025

Serum sphingosine-1-phosphate levels are associated with brain metastasis in

Gang Xu, Yajie Li, Bo An, Bo Pan, Lihua Shang, Yan Yu, Dexin Jia

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Gang XuDepartment of Respiratory and Critical Care Medicine, Chongqing University Three Gorges Hospital, Chongqing, China.
Yajie LiDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Bo AnDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Bo PanDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Lihua ShangDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Yan YuDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Dexin JiaDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo investigate the association between serum sphingosine-1-phosphate (S1P) levels and brain metastasis in EGFR-mutant lung adenocarcinoma (LUAD).

methodsSerum S1P levels were analyzed in 103 LUAD patients. The baseline characteristics of the 103 patients in this study included the following: the overall cohort consisted of 50.49% males and 49.51% females. The average age of the cohort was 69.50 years (SD = 59.12). Regarding EGFR mutations, 52 patients (50.49%) had wild-type EGFR, 19 patients (18.45%) had EGFR Ex19Del, and 32 patients (31.07%) had the L858R mutation. Logistic regression models and competing risk Cox analyses were used to evaluate the association between S1P levels and brain metastasis. Kaplan-Meier curves assessed cumulative brain metastasis incidence over time.

resultsSerum sphingosine-1-phosphate (SIP) levels were measured with the following results (mean ± SD): wild-type EGFR, 970.44 ± 344.37 nmol/L; Ex19Del, 1,246.41 ± 306.93 nmol/L; and L858R, 1,333.21 ± 385.08 nmol/L (

conclusionElevated serum S1P levels are significantly associated with brain metastasis in EGFR-mutant LUAD patients. S1P may serve as a biomarker for brain metastasis risk and a potential therapeutic target.

Indexed as

Adenocarcinoma of LungBiomarkers, TumorBrain NeoplasmsLung NeoplasmsLysophospholipidsMutationSphingosineAgedAged, 80 and overErbB ReceptorsFemaleHumansKaplan-Meier EstimateMaleMiddle AgedPrognosisBiomarkers, TumorEGFR protein, humanErbB ReceptorsLysophospholipidsSphingosinesphingosine 1-phosphateBrain metastasisEGFR-mutationEGFR wild-typelung adenocarcinomaS1P

Identifiers

PMID40742314
PMCPMC12408039

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.